Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
upgraded at UBS from Neutral to Buy, UBS said. $40 price target. Survey suggests that demand is stabilizing.
downgraded at Goldman to Buy from Neutral, Goldman Sachs said. Company also removed from the Conviction List.
upgraded at Sterne Agee from Neutral to Buy, Sterne Agee said. $36 price target. Valuation call, following the recent pullback.
upgraded at Credit Suisse to Outperform from Neutral. Strong fundamentals and more deals coming, Credit Suisse said. Price target raised to $32 from $25.
rated new Buy at Goldman. $48 price target. Company can deliver consistent cash flow growth.
downgraded at JP Morgan from Neutral to Underweight. $42 price target. Consensus estimates appear too high.
upgraded at FBR from Market Perform to Outperform, FBR Capital Markets said. $17 price target. Company has the most relative excess capital.
estimates, target boosted at Goldman. Shares of FSLR now seen reaching $190, according to Goldman Sachs. Estimates also upped, given improved volume visibility. Buy rating.
downgraded at UBS from Buy to Neutral, UBS said. Valuation call, based on a $180 price target.
downgraded at BB&T to Hold, BB&T Capital said. Company guided toward lower near-term margins.
upgraded at Deutsche to Buy, Deutsche Bank said. Company is seeing solid growth an boosted its dividend. $60 price target.
upgraded at Soleil from Accumulate to Buy, Soleil Securities said. Valuation call, based on a $54 price target. Hospital spending appears to be improving.
rated new Hold at Canaccord. $28 price target. Stock is pricing in the potential for increased competition.
rated new Buy at Kaufman. $24 price target. Stock trades at a significant discount to its peers.
downgraded at Deutsche to Hold. $19 price target. Company has limited earnings visibility.
downgraded at Piper to Underweight. $15 price target. Company is seeing lower growth across the board.
downgraded at ThinkEquity from Buy to Hold, ThinkEquity said. $18 price target. Company slashed its forward guidance.
downgraded at Citi from Buy to Hold on disappointing 4Q10 results, Citigroup said. Price target cut to $20 from $26.
downgraded at Baird from Outperform to Neutral. $18 price target. Company lowered its earnings outlook.
upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $59 price target. Stock has pulled back 13% over the past two months.
upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $37 price target. Company boosted forward guidance after a strong quarter.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Company was also added to the Conviction List, as it consistently delivers the best business trends. $38 price target.
This article was written by a staff member of TheStreet.